HLA-E and cancer: In patients with EBV‐associated malignancies, LMP1‐containing TDEs may mediate immunosuppressive effects on TILs.163 HLA‐E is another nonclassical MHC‐I molecule, and can bind to the NK cell inhibitory receptor 2A (NKG2A)164 to inhibit T‐cell or NK cell‐mediated cytolytic activity162, 165, 166 and lead to cancer immune escape (Figure 2).